The structures of two novel 3,4-seco-lanostane-type triterpenes isolated from the sclerotium of Poria cocos were established to be 16alpha-hydroxy-3,4-seco-lanosta-4(28),8,24-triene-3,21-dioic acid (1; poricoic acid G) and 16alpha-hydroxy-3,4-seco-24-methyllanosta-4(28),8,24(24(1))-triene-3,21-dioic acid (2; poricoic acid H) on the basis of spectroscopic methods. These two, and eight other known compounds isolated from the sclerotium, poricoic acid B (3), poricoic acid A (4), tumulosic acid (5), dehydrotumulosic acid (6), 3-epidehydrotumulosic acid (7), polyporenic acid C (8), 25-hydroxy-3-epidehydrotumulosic acid (9), and dehydroabietic acid methyl ester (10), showed potent inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation induced by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). Evaluation of the cytotoxicity of compounds 1 and 4 against human cancer cell lines revealed that 1 was significantly cytotoxic to leukemia HL-60 cells [GI(50) (concentration that yields 50% growth) value 39.3 nM], although it showed only moderate cytotoxicity to the other cells. Compound 4 exhibited moderate cytotoxicity to all of the cancer cell lines tested.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/np0103721 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Poricoic acid A attenuates renal fibrosis by inhibiting endoplasmic reticulum stress-mediated apoptosis.
Braz J Med Biol Res
November 2024
Clinical Experimental Center, Xi'an Engineering Technology Research Center for Cardiovascular Active Peptides, Northwest University Affiliated Xi'an International Medical Center Hospital, Xi'an, Shaanxi, China.
Article Synopsis
- Renal fibrosis is a key issue in chronic kidney disease leading to kidney failure, and there are currently no therapies to stop its progression.
- A study found that Poricoic acid A (PAA), derived from Poria cocos, effectively reduces renal damage and collagen buildup in a mouse model of renal fibrosis caused by unilateral ureteral obstruction.
- PAA works by inhibiting processes like epithelial-to-mesenchymal transition (EMT) and endoplasmic reticulum stress (ERS), as well as reducing apoptosis in kidney cells, indicating its potential as a treatment for renal fibrosis.
Poricoic acid a ameliorates high glucose-induced podocyte injury by regulating the AMPKα/FUNDC1 pathway.
Mol Biol Rep
September 2024
Department of Endocrinology, Zhongnan Hospital of Wuhan University, No.167 Donghu Road, Wuhan, 430071, Hubei, China.
Background: Poricoic acid A (PAA), a major triterpenoid component of Poria cocos with anti-tumor, anti-fibrotic, anti-inflammatory, and immune-regulating activities, has been shown to induce podocyte autophagy in diabetic kidney disease (DKD) by downregulating FUN14 domain containing 1 (FUNDC1). This study aimed to identify the role of adenosine monophosphate-activated protein kinase alpha (AMPKα) in PAA-mediated phosphorylation of FUNDC1 in podocyte injury occurring in the pathogenesis of DKD.
Methods And Results: A cellular model of renal podocyte injury was established by culturing MPC5 cells under high-glucose (HG) conditions.
The investigation of potential mechanism of Fuzhengkangfu Decoction against Diabetic myocardial injury based on a combined strategy of network pharmacology, transcriptomics, and experimental verification.
Biomed Pharmacother
August 2024
Department of Cardiology, Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China. Electronic address:
Background And Objectives: Diabetic cardiomyopathy (DCM) is a cardiac condition resulting from myocardial damage caused by diabetes mellitus (DM), currently lacking specific therapeutic interventions. Fuzhengkangfu decoction (FZK) plays an important role in the prevention and treatment of various cardiovascular diseases. However, the efficacy and potential mechanisms of FZK are not fully understood.
View Article and Find Full Text PDFIntegrated serum pharmacochemistry, network pharmacology, and pharmacokinetics to clarify the effective components and pharmacological mechanisms of the proprietary Chinese medicine Jinkui Shenqi Pill in treating kidney yang deficiency syndrome.
J Pharm Biomed Anal
September 2024
School of Pharmacy, China Medical University, Shenyang 110122, China. Electronic address:
The proprietary Chinese medicine Jinkui Shenqi Pill (PCM-JKSQP) is a classic compound used for the effective clinical treatment of kidney yang deficiency syndrome (KYDS), a metabolic disease accompanied by kidney injury. However, its active ingredients and therapeutic mechanisms are not clear. This study employed serum pharmacochemistry, network pharmacology, and pharmacokinetics (PK) to identify the bioactive components of PCM-JKSQP and preliminarily clarify its mechanism in treating KYDS.
View Article and Find Full Text PDFPoricoic acid A promotes angiogenesis and myocardial regeneration by inducing autophagy in myocardial infarction.
Tissue Cell
June 2024
Department of Cardiology, the Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin 130000, China.
Article Synopsis
- * The research found that PAA treatment improved cell proliferation and reduced apoptosis in human cardiac microvascular endothelial cells (HCMECs) subjected to oxygen glucose deprivation, simulating MI.
- * PAA was shown to enhance autophagy, promote angiogenesis, and activate the AMPK/mTOR signaling pathway, suggesting its potential as a therapeutic agent for MI recovery.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!